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 Abstract 
 
The androgen receptor (AR) is a key driver of prostate cancer (PC) development. Anti-androgens 
effectively inactivate the AR, but subsequent AR reactivation progresses the disease to castrate-
resistant prostate cancer (CRPC). Constitutively active AR splice variants (AR-Vs) that function 
unchallenged by current AR-targeted therapies are key drivers of CRPC. Currently, very little is 
known about the regulation of AR-Vs at the chromatin level.   
Here we show that the pioneer factor GATA2 is a critical regulator of AR-Vs. Furthermore, we 
demonstrate that the GATA2 cistrome in CRPC shares considerable overlap with bromodomain and 
extraterminal (BET) proteins and are co-dependent for DNA binding. GATA2 activity is compromised 
by BET inhibitors which attenuates the pioneering role of GATA2 in CRPC. In all, this study indicates 
that GATA2 is a critical regulator of AR-V-mediated transactivation and is sensitive to BET inhibitors 
signifying these agents may be efficacious in CRPC patients which overexpress GATA2. 
 
Implications: We have defined novel mechanisms of AR-V and GATA2 regulation in advanced 
prostate cancer that could be therapeutically exploited. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
PC is the second most commonly diagnosed cancer in men globally with 1.3 million annual diagnoses 
worldwide (World Health Organisation, 2018). At presentation, PC growth is androgen-dependent 
hence the mainstay of treatment is androgen deprivation therapy (ADT) in combination with anti-
androgens. Although initially effective, patients eventually relapse with more aggressive disease 
termed CRPC which is largely fatal.   
The AR is a member of the nuclear hormone receptor family of transcription factors and is the 
primary target of ADT. Androgens, in the form of testosterone, and its more potent metabolite 
dihydrotestosterone (DHT), provide androgenic signals which are transmitted via the AR and 
ultimately drive PC progression [1]. Importantly, AR signalling persists in CRPC due to several well 
characterised molecular mechanisms [2], including AR gene amplification and mutation, which has 
justified the development of second generation anti-androgens, such as enzalutamide and 
apalutamide [3, 4]. These compounds are used clinically to treat CRPC, but response rates of 
approximately 50% [5, 6] and development of resistance limits their efficacy in the advanced setting. 
A major contributing factor to the compromised activity of second generation anti-androgens in 
CRPC is the expression of AR splice variants (AR-Vs) which are bone fide drivers of AR signalling 
programs in CRPC. Critically, AR-Vs, such as the clinically-relevant AR-V7 and AR-V3 isoforms [7], lack 
the ligand binding domain (LBD), but retain the transcriptionally potent N-terminal domain (NTD) 
and DNA-binding domain (DBD) allowing AR-Vs to drive gene expression independently of hormone 
stimulation, and critically, evade all current direct AR-targeting therapies [8-10]. This poses a major 
clinical challenge as the most recent observations indicate approximately 80% of CRPC patients 
express these constitutively active forms of the receptor [11].  
Without the availability of direct AR-V antagonists, recent research has focused on establishing if AR-
V coregulatory proteins represent tractable targets to attenuate AR-V function [12-14]. AR-V 
chromatin occupancy at both proximal promoters and distal enhancers of target genes is required 
for canonical AR gene transactivation [15]. Proteins that control enrichment of AR-Vs at these sites 
may therefore represent novel therapeutic targets. Consistent with this, GATA2 and FOXA1 are 
pioneer factors that have been shown in multiple studies to engage and reconfigure condensed 
chromatin [16, 17] to facilitate DNA binding of AR-FL [15]. Together, GATA2 and FOXA1 co-occupy 
approximately 55% of the AR-FL cistrome in PC [15]. FOXA1 and GATA2 are critical for AR-FL 
recruitment to cis-regulatory elements of AR target genes and promote efficient AR-FL 
transcriptional activity [15, 18]. However, our understanding of how AR-Vs are controlled by pioneer 
factors is ill-defined, particularly with respect to GATA2. Importantly, our previous data indicated 
that only 41% of the AR-V transcriptome was dependent upon FOXA1 [12], suggesting that GATA2 
may contribute to regulation of AR-V-target genes in CRPC.  
The GATA family of transcription factors, which consists of GATA1-6, are differentially expressed 
across diverse cell lineages and play numerous important tissue-specific roles in a range of 
physiological processes, including erythrocyte differentiation and proliferation, as well as  
cardiovascular and gastrointestinal development [19-23]. GATA transcription factors contain two 
zinc-fingers, which enable DNA and cofactor interactions [24], and are directly acetylated which 
controls DNA binding capacity and target gene transactivation [25]. GATA2 is the most highly 
expressed member of the GATA family in the prostate and its expression correlates with Gleason 
score, metastasis and invasiveness of PC [26, 27]. Our understanding of the role of GATA2 in 
prostate transcriptional regulation is largely limited to its ability to act as a pioneer factor for AR-FL. 
Importantly, GATA2 and AR are involved in an auto-regulatory loop in PC cells. GATA2 gene 
expression is elevated by ADT and anti-androgens, which in turn upregulates GATA2-mediated 
transactivation of AR expression via binding to transcriptional regulatory sites approximately 5.5 and 
4.6 kb upstream of the AR gene [15, 26]. Moreover, by engaging and priming regulatory elements of 
canonical AR-target genes, GATA2 enhances AR-FL activity by facilitating chromatin deposition of the 
active receptor at target loci. Importantly, depletion of GATA2 compromises activation of the AR-FL 
transcriptome in the LNCaP PC cell line [26]. Consistent with these observations, the GATA2 inhibitor 
K7174 was shown to diminish in vivo growth of AR- and GATA2-expressing LNCaP-abl xenografts 
[26]. 
Critically, outside of the demonstration that GATA2 is important for facilitating ectopically-expressed 
AR-V7-mediated FKBP5 transactivation in LNCaP cells, there is very little known about the global 
requirement of GATA2 for AR-V-mediated transactivation in physiologically-relevant models. 
Furthermore, our knowledge of what governs GATA2 chromatin occupancy to enable it to function 
as an AR-V pioneer factor is extremely limited and needs addressing. To this end, we show that 
approximately 36% of the AR-V transcriptome is dependent upon GATA2, and depletion of the 
pioneer factor diminishes expression of an AR-V-driven gene signature important for CRPC 
progression. Using chromatin immunoprecipitation (ChIP)-sequencing, we show that GATA2 
chromatin occupancy overlaps with multiple members of the bromodomain and extraterminal (BET) 
family of transcriptional regulators, including BRD2, BRD3 and BRD4. Furthermore, we show that 
GATA2 is acetylated and interacts with BET proteins in a bromodomain-dependent manner. 
Consistent with this mode of interaction, we demonstrate that the pan-BET inhibitor JQ1 attenuates 
GATA2-BET interaction and compromises GATA2 chromatin binding and transcriptional competency 
suggesting that GATA2 is dependent on BET proteins for its role as a pioneer factor. Overall, our data 
indicates a novel mechanism of regulating GATA2 binding to AR-V target genes that involves BET 
proteins and that this dependence may sensitise GATA2-driven CRPC to BET inhibitors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and methods 
 
Online gene expression profiling 
PRIM1, TRIM14 and RAP1GAP mRNA expression was assessed by analysing pre-processed gene 
expression microarray/RNA-seq datasets from the Taylor et al. [28] (GSE21032) study. Gene 
expression values were downloaded and plotted according to clinical disease type: benign prostatic 
hyperplasic (BPH), localised prostate cancer (PCa) and metastatic castrate-resistant prostate cancer 
(mCRPC). Outliers are shown as ●, ▪ and ▲ respectively, (* = p ≤ 0.05, ns = p ≥ 0.05). 
Plasmids 
pFLAG-GATA2 (Addgene plasmid #1418), GFP-BRD2 (Addgene plasmid #65376) and GFP-BRD3 
(Addgene plasmid #65377) were purchased from Addgene. pFLAG-CMV-BRD4-short (1-700) was 
created by cloning the truncated BRD4 sequence, amplified by PCR using the primers BRD4F: AGG 
AGA TAT ACC ATG AAG CTT ATG TCT GCG GAG AGC GGCCC and BRD4SR: CAG CAC TAG TGG ATC CTC 
AGG ACG AGA AGC CCT TCA TCT  into Bam H1 and Hind III sites of pFLAG-CMV2 (Sigma). The 
QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) was used to introduce mutations 
into mammalian expression vectors by PCR according to the manufacturer’s instructions. 
Mutagenised plasmid DNA was used to transform competent E.coli. Colonies were picked, 
propagated and DNA extracted. Colonies were screened for desired mutations using Sanger 
sequencing (Genewiz). 
Cell culture, siRNA transfections and DNA transfections  
CWR22Rv1 (ATCC® CRL-2505), VCaP (ATCC® CRL-2876™) and HEK293T (ATCC® CRL-3216™) 
authenticated cell lines were purchased from ATCC and maintained at 5% CO2 and at 37ᵒC. Each cell 
line was tested for mycoplasma every 3 months and grown to maximum of 35 passages. CWR22Rv1 
and HEK293T were maintained in RMPI-1640 (R5886, Sigma Aldrich) supplemented with 10% (v/v) 
foetal bovine serum (HyClone) and 2 mM L-glutamine (Sigma Aldrich). VCaP cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (R6171, Sigma Aldrich) supplemented with 10% (v/v) foetal 
bovine serum and 2 mM L-glutamine. For experiments requiring steroid-depleted conditions, 
CWR22Rv1 cells were cultured in RPMI-1640 supplemented with 10% (v/v) dextran-coated charcoal-
stripped foetal bovine serum (HyClone) and 2 mM L-glutamine. VCaP cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (R6171, Sigma Aldrich) supplemented with 10% (v/v) dextran-
coated charcoal-stripped foetal bovine serum (HyClone) and 2 mM L-glutamine. For siRNA 
transfections, siRNAs (Supplementary Table S1) were transfected using Lipofectamine® RNAiMAX 
transfection reagent (Thermo) to a final concentration of 25 nM (as described in [29]). For DNA 
transfections, plasmid DNA was transfected using TransIT®-LT1 transfection reagent (Mirus).  
RT-qPCR and micro-array gene expression analysis 
RNA exactions were performed using TRIzol® Reagent (Life Sciences, Invitrogen) according to the 
manufacturer’s recommendations and resultant RNA was reverse transcribed using the M-MLV 
reverse transcription kit (Promega). Changes in gene expression were quantified using quantitative 
RT-PCR incorporating cDNA and AR- and GATA2-target gene-specific primers (Supplementary Table 
S2). RPL13A was used as a house keeping gene. Data is presented as mean normalised gene 
expression of 3 independent experiments ± SEM (* = p ≤ 0.05, ns = p ≥ 0.05).  
For micro-array studies, RNA was extracted as described above and subject to differential gene 
expression analysis using the Illumina HT-12 BeadChip array (AROS); the GEO accession number for 
this data is GSE124999.  Array processing, background correction, normalisation and quality control 
checks were performed using the R package ‘Lumi’. Probe intensity values were converted to VSD 
(variance stabilized data) using variance stabilising transformation. The robust spline normalization 
(RSN) was used as an array normalisation method. Poor quality probes (detection threshold < 0.01), 
and probes that are not detected at all in the remaining arrays were removed prior to downstream 
analysis. The remaining probe (22,380) normalised intensity was used in the differential expression 
analysis. Differentially expressed genes were analysed using the Gene Set Enrichment Analysis 
(GSEA) tool (Broad Institute). Differentially expressed genes were ranked from highest to lowest by 
Log fold change (LogFC). GSEA was performed using classical weighting of pre-ranked genes. 
Normalised enrichment scores (NES) and false discovery rates (q-value) were computed using 1000 
random permutations of pre-ranked genes. Using GSEA, the GATA2 gene signature was compared to 
the AR-V gene signature from our previous study [12] to assess the correlation between signatures. 
The GATA2 gene signature was also assessed against the ‘Gene Ontology (GO)’ and ‘Oncogenic 
signatures’ data sets using GSEA. Database for Annotation, Visualization and Integrated Discovery 
(DAVID) v6.8 was also used to identify pathways impacted by GATA2 depletion. The GATA2-LNCaP 
gene signature was a kind gift from Nicholas Mitsiades [26], the c-Myc gene signature was 
downloaded from Barfeld et al. [30] and the 0.5 µM I-BET762 LNCaP gene signature was downloaded 
from Wyce et al. [31].  
Immunoprecipitation, chromatin immunoprecipitation (ChIP) and western blotting 
Immunoprecipitation was performed as in [32] using an anti-GATA2 antibody (Sigma Aldrich 
HPA005633) or an anti-Flag antibody (Sigma Aldrich) and resultant immunoprecipitates subject to 
western blot analysis using the following antibodies: anti-α-tubulin (Sigma Aldrich), anti-AR (N20) 
(Santa Cruz Biotechnology (sc-816)), anti-AR (BD) (BD biosciences (#9441)), anti-GATA2 (Sigma 
Aldrich (HPA005633)), anti-BRD4 (Bethyl (A301-985A100)), anti-acetylated-lysine (Cell Signalling 
(#9441)), anti-histone H1 (Santa Cruz Biotechnology (sc-8030)), anti-V5 (Santa Cruz Biotechnology 
(sc-271944)) and anti-p300 (Abcam (ab14984)). 
ChIP was performed as in [33] and re-ChIP was performed as in [32]. Cells were seeded at a density 
of 5 x 106 per 150 mm dish and typically cultured in steroid-depleted conditions for 72 hours total. 
For ChIP experiments involving GATA2 knockdown, GATA2 was depleted from VCaP and CWR22Rv1 
cells for 48 hours prior to ChIP. For JQ1 treated ChIP experiments, VCaP and CWR22Rv1 cells were 
treated with 1 µM JQ1 for 24 hours prior to ChIP. Typically, 80 µg of chromatin was incorporated 
into each ChIP and 2 µg of the following antibodies: anti-AR (N20), anti-AR (BD), anti-GATA2, anti-
BRD4 (Abcam (A301-985A100)), anti-FOXA1 (Abcam (ab128874)) and isotype controls (Diagnode 
(C15410206)). DNA fragments retrieved by ChIP were analysed by quantitative-PCR using the 
primers described in Supplementary Table S3. Data is presented as mean normalised percentage 
input of 3 independent experiments ± SEM (* = p ≤ 0.05, ns = p ≥ 0.05). 
For ChIP-sequencing experiments in VCaP cells, 5 ng total DNA from replicate GATA2 ChIPs were 
incorporated into library preparation and subsequently sequenced (30 million reads per sample) on 
an Illumina NextSeq 500 System (performed by Genomics4Life). ChIP-Seq data is publically accessible 
with the accession number GSE125236. Fastq files for BRD2, BRD3, BRD4, AR -/+ DHT were 
downloaded from Asangani et al. [14], c-Myc and E2F1 fastq files were downloaded online from 
Barfeld et al. [30] and Xu et al., 2016 [34], respectively and the LNCaP GATA2 BED file was a kind gift 
from Nicholas Mitsiades [26]. The raw read data were aligned to the human genome hg38 assembly 
using Bowtie2 with default parameters. Non-uniquely aligned reads and aligned reads with more 
than two mismatches were removed using an in-house script. Potential PCR duplicates were 
removed using Picard Mark Duplicate. Regions of genomic enrichment were identified using MACS2 
with default settings (q < 0.05). Bioconductor package ‘DiffBind’ was used for differential binding 
analysis between knockdown/treated and control samples. Bioconductor package ‘ChipPeakAnno’ 
was used to annotate the identified binding regions. For motif analysis, the peak summits returned 
from MACS2 peak calling were extended 100 bp up and downstream for the strongest 100 GATA2 
peaks. DNA sequences were retrieved and submitted to ‘MEME-suite’ (www.meme-suite.org).  
Live cell imaging and cell counts 
For live cell imaging, the Incucyte® ZOOM was used to measure cell confluence over a period of 120 
hours. Cells were seeded on to an appropriate vessel 24 hours prior to measuring cell confluence. 
Following seeding, the appropriate cellular manipulation was applied (siRNA transfection) to cells. 
Images of the vessel were taken every 6 hours for 120 hours. Proliferation was measured as cell 
confluence. Each experiment was performed in triplicate, with 3 technical replicates per 
experimental arm. Percentage confluence was normalised to the 0 hour time point and presented as 
a mean normalised fold change in confluence ± SEM (* = p ≤ 0.05, ns = p ≥ 0.05). For cell counts, cells 
were seeded into a 12-well culture vessel for 96 hours. Cells were washed, trypsinised and counted 
using a haemocytometer. A mean cell count for each sample was calculated from counting the 
number of cells in each experimental arm 5 times. Each experimental arm was performed in 
triplicate (technical replicates) and each experiment was performed independently in triplicate. Data 
represents mean normalised cell counts ± SEM (* = p ≤ 0.05, ns = p ≥ 0.05). 
Statistical analysis 
Statistical analysis was performed in Prism 7 (GraphPad) using a one-way ANOVA followed by a 
Bonferroni multiple correction test or an unpaired two-tailed student’s t-test (* = p ≤ 0.05, ns = p ≥ 
0.05).  
 
  
Results 
 
GATA2 regulates AR-V transcriptional activity in models of CRPC 
We firstly assessed the effect of GATA2 depletion on a number of canonical AR-V-target genes in the 
AR-V-expressing CWR22Rv1 CRPC cell line. To discriminately assess AR-V-mediated transactivation, 
CWR22Rv1 cells were grown in steroid-depleted conditions supplemented with 10 µM enzalutamide 
to mimic maximal castrate conditions [12]. As expected, enzalutamide did not impact AR-target gene 
expression in CWR22Rv1 cells (Figure 1A). In contrast, compared to a non-silencing control (siScr), 
depletion of GATA2 (siGATA2) for 48 hours markedly reduced the expression of AR target genes PSA, 
KLK2 and TMPRSS2 in CWR22Rv1 cells grown in the presence and absence of enzalutamide (Figure 
1A). This was confirmed using a second GATA2 targeting siRNA (Supplementary Figure 1A). Western 
analysis of CWR22Rv1 cells depleted of GATA2 demonstrated reduced AR-V protein levels (Figure 
1B) which is consistent with previous findings from CWR22Rv1 cells [26] indicating GATA2 regulates 
both expression and transcriptional competency of AR-Vs. Importantly, expression of the AR-V-
target gene UBE2C was unaffected by knockdown of GATA2 (Figure 1A, Supplementary Figure 1A), 
suggesting that GATA2 regulates discriminate AR-V-mediated transactivation and the effect of 
GATA2 knockdown on PSA, KLK2 and TMPRSS2 is not exclusively a consequence of diminished AR-V 
protein levels. Furthermore, interrogating ChIP-sequencing data from VCaP cells demonstrated 
GATA2 enrichment at PSA, KLK2 and TMPRSS2 cis-regulatory elements, but not at UBE2C, confirming 
that GATA2 controls AR-V function at specific target loci (Supplementary Figure S1B).   
Given that GATA2 facilitates AR-FL chromatin deposition, we next assessed the impact of GATA2 
depletion on AR-V chromatin binding. CWR22Rv1 cells grown in maximal castrate conditions 
transfected with control (siScr) or GATA2 (siGATA2) siRNAs for 48 hours were subject to ChIP using 
anti-GATA2 and –N-terminal-specific AR antibodies. As shown in Figure 1C and Figure 1D, GATA2 and 
AR-Vs were enriched at PSA and TMPRSS2 enhancers and knockdown of GATA2 significantly reduced 
AR-V chromatin occupancy at these cis-regulatory elements (Figure 1D). Immunoblotting of the ChIP 
chromatin extractions demonstrated that GATA2 was successfully depleted and, as expected, this 
modestly reduced global AR-V chromatin binding (Supplementary Figure S2). Importantly, AR-FL was 
not detected in the chromatin extractions which is a consequence of the maximal castrate growth 
conditions and supports the concept that the AR species detected by ChIP are AR-Vs and not AR-FL.  
 
 
GATA2 depletion downregulates a distinct subset of AR-V-driven target genes  
To examine the role of GATA2 in controlling global AR-V-mediated transactivation, we depleted 
GATA2 in CWR22Rv1 cells for 48h in maximal castrate conditions and performed transcriptomic 
analysis. 2333 genes were significantly altered upon GATA2 knockdown; with 1193 and 1140 genes 
demonstrating up- and down-regulation, respectively. Comparing the GATA2 transcriptome to our 
AR-V and FOXA1 gene signatures derived from CWR22Rv1 cells [12], we demonstrate that GATA2 
regulates 36% (856/2367) of genes controlled by AR-Vs and 30% (522/1722) of genes regulated by 
FOXA1 (Figure 2A). When considering genes which are altered by -/+ 1.5-fold or greater, we show 
that GATA2 knockdown up-regulates 168 genes and down-regulates 113 genes (Supplementary 
Figure S3). Overlapping these genes with our in-house AR-V transcriptome, we demonstrate that 
GATA2 regulates approximately 10% of highly induced AR-V genes and 12% of highly repressed AR-V 
genes. To confirm role of GATA2 in AR-V regulation, two AR-V-induced genes identified by our 
microarray analysis, CDC25A and EXO1, were validated by RT-qPCR (Supplementary Figure S3).  
Gene Set Enrichment Analysis (GSEA) demonstrated significant enrichments between the GATA2 and 
AR-V global gene signatures; genes down-regulated upon AR-V depletion were negatively enriched 
for genes repressed by GATA2 knockdown and vice versa (Figure 2B), indicating that GATA2 
depletion impacts strongly on AR-V transcriptional activity. Interestingly, 42% (181/426) of the genes 
which are induced by GATA2 (LogFC < -0.4) were overexpressed in two CRPC gene sets re-analysed 
by Urbanucci et al. [28, 35] indicating that a large proportion of GATA2-regulated genes are clinically 
relevant (Figure 2C). Furthermore, of the 181 GATA2-regulated CRPC genes, 41% were co-regulated 
by AR-Vs suggesting that GATA2 plays an important role in controlling a CRPC-associated AR-V gene 
signature in advanced disease (Figure 2D, Supplementary Table S2). Gene ontology also indicated 
that GATA2 drives expression of clinically-relevant genes involved in cell cycle regulation 
independently of AR-Vs (Supplementary Figure S4A). To identify cellular processes which are 
perturbed by GATA2 depletion, GSEA was performed using the 2333 GATA2-regulated genes against 
the ‘GO’ GSEA datasets. 291 GO datasets were significantly deregulated upon GATA2 depletion 
(Supplementary Table S1, Figure 2E, top 5 negatively enriched GO biological processes shown), 
including a negative enrichment of transcripts involved in the cell cycle (Figure 2F). Concordant with 
these findings, GATA2 depletion in CWR22Rv1 cells grown in castrate conditions resulted in reduced 
cell proliferation (Figure 2G and Supplementary Figure S4B) which is consistent with compromised 
AR-V signalling.  
 
 
GATA2 regulates the transcriptional activity of other oncogenic transcription factors 
Given that less than half of the GATA2-regulated CRPC genes were co-regulated by AR-Vs, we 
speculated that GATA2 controls activity of other oncogenic transcription factors to facilitate disease 
progression. To this end, we performed GSEA using the 2333 GATA2 regulated genes against the 
‘Oncogenic signatures’ GSEA dataset. 55 oncogenic signatures were deregulated upon GATA2 
depletion (Supplementary Table S1 and Figure 3A, top 10 negatively enriched shown), including c-
Myc and E2F1. Transcripts induced by c-Myc and E2F1 were significantly negatively enriched for 
transcripts regulated by GATA2 (Figure 3B) indicating a potential regulatory role of GATA2 for both 
transcription factors. To further investigate the dependency of c-Myc on GATA2, a c-Myc-induced 
gene signature [30] was compared to a GATA2 gene signature [26], both of which were derived from 
LNCaP cells. Genes induced by c-Myc expression were found to be significantly negatively enriched 
for genes which are regulated by GATA2 (Figure 3C). Moreover, interrogating publically-available c-
Myc, E2F1 and GATA2 ChIP-seq data-sets from LNCaP cells, we identified respective overlaps of 11% 
and 10% between the cistromes of GATA2 and those of c-Myc and E2F1 (Figure 3D), validating the 
regulatory role of GATA2 on other oncogenic transcription factors outside of AR-Vs. 
 
Bromodomain and extraterminal family proteins interact with GATA2 in a bromodomain-
dependant manner 
Acetylation of GATA family members at multiple lysine residues enhances DNA binding [25], and in 
the case of GATA1, also facilitates interaction with the BET protein, BRD3 in erythroid cells [36]. 
Whether GATA2 acetylation occurs in non-erythroid cells and impacts on interactions with BET 
proteins is ill-defined. To this end, ectopically-expressed Flag-tagged GATA2 immunoprecipitated 
from HEK293T cells, grown in the presence and absence of the histone deacetylase (HDAC) inhibitor 
TSA, was subject to western analysis using a pan acetyl-lysine antibody. As shown in Figure 4A, we 
detected an acetylated form of GATA2 in the presence of TSA, suggesting that, like GATA1, GATA2 is 
acetylated and this process is under tight control by the reversible effects of histone 
acetyltransferases (HATs) and HDACs.  
We hypothesised that GATA2 and BET family members interact and this interaction is dependent 
upon the bromodomains of GATA2. HEK293T cells were transfected with a Flag-tagged BRD4 
construct encoding a truncated form of BRD4, termed BRD4S (amino acids 1-700 containing both 
bromodomains (BD) 1, BD2 and the extraterminal domain) and subject to endogenous GATA2 
immunoprecipitation. Immunoblotting of resultant immunoprecipitates detected the truncated form 
of BRD4, suggesting that the BET protein and GATA2 interact (Figure 4B). Importantly, a 24-hour 
treatment of BRD4S-transfected cells with 1 µM of the BET inhibitor JQ1 attenuated the GATA2-
BRD4S interaction suggesting that this interaction is mediated by the BDs of BRD4S (Figure 4B). BD1 
and BD2 of BET proteins differ vastly in their substrate-binding capacities, but together enable 
simultaneous, bivalent interaction with distinct acetylated lysine residues. To examine the 
bromodomain requirements for the BRD4-GATA2 interaction, HEK293T cells were transfected with 
wild-type, BD1 (BRD4SmBD1)-mutant or BD2 (BRD4SmBD2)-mutant Flag-tagged BRD4S derivatives 
for 48 hours then subject to GATA2 immunoprecipitation. Immunoblotting GATA2 
immunoprecipitates with an anti-Flag antibody demonstrated that mutation of BD1, but not BD2, 
severely diminished the GATA2-BRD4S interaction suggesting that BD1 mediates the BRD4S-GATA2 
interaction (Figure 4C). Interestingly, mutation of key residues in BD2 was found to increase 
association between BRD4S-GATA2 suggesting that BD2 may counteract binding of BRD4 to GATA2 
(Figure 4C). In addition to BRD4, we also demonstrate that GATA2 interacts with BRD3, and to a 
lesser extent BRD2 (Figure 4D), indicating possible redundancy between BET family members in 
potentiating GATA2 regulation.   
 
BRD4 and GATA2 are co-dependent on each other for chromatin occupancy 
Given that both GATA2 and BRD4 are chromatin-associated proteins, we next investigated interplay 
between the two proteins at the chromatin level. Re-ChIP experiments performed in VCaP cells using 
consecutive BRD4 and GATA2 immunoprecipitations demonstrated that GATA2 and BRD4 are closely 
associated on the gene enhancers of PSA and TMPRSS2 (Figure 4E). Moreover, depleting GATA2 
(siGATA2) for 48 hours in VCaP cells markedly diminished BRD4 chromatin occupancy at PSA and 
TMPRSS2 cis-regulatory elements compared to control (siScr) (Figure 4F), without impacting on total 
BRD4 protein levels (Supplementary Figure S5A), which is consistent with previous findings 
describing a dependency of BRD3 on GATA1 for chromatin binding [36]. We next investigated if a 
reciprocal relationship existed between GATA2 and BET proteins by assessing the sensitivity of 
GATA2 chromatin occupancy to BET inhibition using 1 µM JQ1. As shown in Figure 4G, GATA2 
enrichment at the PSA and TMPRSS2 enhancers in VCaP cells was significantly reduced upon JQ1 
treatment compared to the DMSO treated control (NT) and was not a consequence of reduced total 
GATA2 levels in response to BET inhibition (Supplementary Figure S5B). Importantly, the dependency 
of GATA2 chromatin association on BET proteins was confirmed using GATA2 ChIP experiments in 
CWR22Rv1 cells treated with 1 µM JQ1 (Supplementary Figure S5C). Moreover, unaltered FOXA1 
chromatin binding in response to JQ1 in VCaP cells (Supplementary Figure S5D) suggests that BET 
inhibition does not indiscriminately down-regulate association of all DNA-binding proteins and 
confirms co-dependency of GATA2 and BET proteins for chromatin occupancy at specific genomic 
loci. 
To understand how JQ1 impacts global GATA2 chromatin association, we performed GATA2 ChIP-seq 
in VCaP cells treated with and without 1 µM JQ1. We chose VCaP cells to conduct these experiments 
because ChIP-Seq data-sets for the BET family members BRD2, BRD3 and BRD4 was publically-
available and hence would enable a more robust assessment of GATA2-BET protein chromatin 
interplay in CRPC. As expected, motif analysis of the 6,901 GATA2 peaks present in both GATA2 ChIP 
replicates (termed the consensus peak set, Supplementary Figure S6A), derived from the control 
experiment, identified the GATA2 response element as the most prominent feature of the 
sequenced peaks (Figure 5A). As shown in Supplementary Figure S6B, GATA2 was enriched at cis-
regulatory elements upstream from the PSA (KLK3), KLK2 and TMPRSS2 genes in both experimental 
replicates and was reduced in response to 1 µM JQ1 treatment. Furthermore, consistent with 
previous reports [26], the distribution of GATA2-binding sites was varied, but distal intergenic and 
intronic loci were the most abundant genomic sites associated with GATA2 (Figure 5B) comprising 
approximately 36% and 26% of the total described peaks, respectively. Comparing the consensus 
GATA2 cistromes between control and 1 µM JQ1-treatment, we identified 1,040 GATA2 binding sites 
(15% of total) which were significantly differentially bound in response to JQ1 treatment (Figure 5C 
and Supplementary Figure S6C). Visualisation of differentially bound sites indicated that sites which 
are more strongly bound by GATA2 were less sensitive to JQ1 treatment and vice versa 
(Supplementary Figure S6D). We hypothesised that GATA2 would be impacted by JQ1 at genomic 
regions co-occupied by the BET family (BRD2, BRD3 and BRD4) and therefore examined the genome-
wide overlap of GATA2 and BET proteins. 56% (3836/6901) of the GATA2 cistrome was co-occupied 
by at least one BET protein (Figure 5D and Supplementary Figure S7A). In addition, we found that 
64% (659/1022) of the JQ1-sensitive GATA2 bound sites were co-occupied by either BRD2, BRD3, 
BRD4 or a combination of BET proteins, such as at the PSA (KLK3), KLK2 and TMPRSS2 enhancers, 
(Figure 5E and Supplementary Figure S7B), suggesting that BET protein occupancy represents a large 
determinant for GATA2 chromatin binding-sensitivity to JQ1.  
To investigate the potential clinical impact of JQ1-mediated GATA2 loss at chromatin, the most 
proximal genes were assigned to the 1,022 genomic binding sites from which GATA2 was lost in 
response to BET inhibition. We identified 916 genes which are potentially impacted by JQ1-mediated 
loss of GATA2. Importantly, 245 of these genes have been demonstrated to be overexpressed in 
CRPC [28, 35, 37] suggesting that JQ1 treatment may attenuate CRPC-associated gene expression by 
preventing GATA2 binding to chromatin (Supplementary Figure S8A; left panel). 157 genes were 
identified which possessed a differentially bound GATA2 site within a gene promoter (-/+ 10 kb from 
TSS). 31% (49/157) of these genes were overexpressed in CRPC reaffirming that JQ1 treatment may 
attenuate CRPC-associated gene expression by preventing GATA2 binding to chromatin 
(Supplementary Figure S8A; right panel) 
BET inhibitors impact global GATA2-regulated gene expression 
To investigate the effect of BET inhibitors on global GATA2-regulated gene expression, we assessed 
the correlation between GATA2-regulated genes [26] and those sensitive to the BET inhibitor I-
BET762 [31] from two publicly available datasets derived from LNCaP cells. Using GSEA, we 
determined that transcripts downregulated by 0.5 µM I-BET762 were significantly negatively 
enriched for transcripts that were regulated by GATA2 and vice versa (Figure 6A). Furthermore, 13% 
of all significantly deregulated transcripts upon GATA2 depletion were strongly (-/+ 2 LogFC) 
deregulated by I-BET762 in LNCaP cells (Supplementary Figure S8B) suggesting that treatment with I-
BET762 impacts global GATA2-regulated gene expression.  
As proof of concept that GATA2 activity is sensitive to BET inhibitors in CRPC, we investigated the 
effect of JQ1 on expression of PRIM1, TRIM14 and RAP1GAP which are all significantly overexpressed 
in advanced PC (Figure 6B). Our ChIP-sequencing data demonstrates that GATA2 is lost from cis-
regulatory elements of PRIM1, TRIM14 and RAP1GAP genes in response to JQ1, which are co-
occupied by BET family members (Figure 6C). We validated this finding using ChIP-qPCR in VCaP cells 
(Figure 6D). Furthermore, GATA2 knockdown in VCaP and CWR22Rv1 cells significantly reduced 
PRIM1 mRNA levels (Figure 6E and Supplementary Figure S8C) indicating that PRIM1 is directly 
regulated by GATA2. To investigate if loss of GATA2 chromatin occupancy by JQ1 impacts PRIM1 
expression, VCaP cells cultured in steroid-depleted conditions were treated with 1 µM JQ1 for 24 
hours. As shown in Figure 6F, JQ1 treatment significantly reduced expression of the CRPC-associated 
gene compared to control. Additionally, PRIM1, TRIM14 and RAP1GAP mRNA was significantly 
downregulated in response to 0.5 µM and 10 µM I-BET762 in VCaP cells (Figure 6G) supporting the 
concept that GATA2-mediated regulation of CRPC-associated genes can be attenuated by BET 
protein blockade.  
In all, our findings indicate that GATA2 is a key regulator of AR-V transcriptional activity in CRPC and 
depletion attenuates cell growth. Furthermore, we show that GATA2 is important for controlling 
other key oncogenic transcription factors which drive aberrant transcriptional programs in CRPC. 
Critically, we show that GATA2 chromatin occupancy is regulated by BET proteins and treatment of 
CRPC cells with JQ1 attenuates GATA2 recruitment to chromatin and expression of GATA2-induced 
CRPC genes. This data advocates the use of BET inhibitors in GATA2-overexpressed prostate 
malignancy. 
 
Discussion 
Although persistent AR signalling is a key driver of disease progression [3, 38], only 50% of CRPC 
patients will respond [5, 6] to the current gold standard AR-targeting treatments and even this is 
short-lived in the majority of cases. One reason for this failure is the expression of numerous 
alternatively spliced forms of the receptor termed AR-Vs in approximately 80% of CRPC [11]. These 
shortened forms of the AR-FL drive an androgenic signalling program without requiring ligand 
stimulation and go unchallenged by all clinically-relevant anti-androgens [39]; hence pose a major 
clinical problem. Although considerable progress has been made in recent years to understand how 
AR-Vs facilitate PC progression, our knowledge of what AR-Vs interact with and how they are 
regulated at the level of chromatin is still lacking. Given that AR-FL transcriptional activity is highly 
dependent upon the pioneer factors FOXA1 and GATA2 [15, 18, 26], it is likely that AR-Vs are also 
subject to this level of regulation. Indeed, several studies have indicated that FOXA1 facilitates 
chromatin association of AR-Vs and is important for controlling approximately 41% of the AR-V 
transcriptome [12]. In contrast, the involvement of GATA2 in global AR-V regulation is considerably 
less well characterised with only one study demonstrating ectopically-expressed AR-V7-mediated 
transactivation of FKBP5 is enhanced by GATA2 in LNCaP cells [26].  
We therefore comprehensively assessed the role of GATA2 in regulating AR-Vs in the physiologically-
relevant CWR22Rv1 CRPC cell line. Consistent with GATA2-mediated regulation of AR-FL [15, 18, 26], 
we have shown that GATA2 is present at cis-regulatory promoter and enhancer elements of the 
canonical AR target genes PSA, KLK2 and TMPRSS2 in maximal castrate conditions. Moreover, siRNA-
mediated GATA2 depletion diminished AR-V chromatin occupancy at these sites and in-turn reduced 
AR-V-driven PSA, KLK2 and TMPRSS2 expression indicating GATA2 regulates the activity of AR-Vs at 
these loci. To assess the involvement of GATA2 in global AR-V-mediated transactivation, we defined 
the GATA2 transcriptome in CWR22Rv1 cells and compared it to our previously published AR-V gene 
set [12]. GATA2 regulated approximately 36% of the AR-V transcriptome and GSEA indicated 
significant enrichments between the two gene sets. Importantly, we observed that a considerable 
number of genes were down-regulated by both GATA2 and AR-V knockdown, validating GATA2 as a 
bona fide pioneer factor for AR-Vs. In the context of AR-FL, both GATA2 and FOXA1 have been 
shown to co-occupy 55% of AR-FL cis-regulatory elements [15]. Consistent with this observation, we 
identified that 62% of AR-V-regulated genes are controlled by both FOXA1 and GATA2 in CWR22Rv1 
cells supporting the concept that reconfiguration of chromatin architecture by multiple pioneer 
factors is critical for AR-V function at a large proportion of target loci.  
Further interrogation of our CWR22Rv1-derived transcriptomic data also provided evidence that 
GATA2 regulates the activity of other oncogenic transcription factors including c-Myc and E2F1. This 
was confirmed in silico using transcriptomic and cistromic data sets derived from LNCaP cells [30, 34] 
which indicated considerable DNA-binding site and target gene overlaps between GATA2 and both c-
Myc and E2F1. Consistent with GATA2 regulating the transcriptional competency of AR-Vs and other 
key CRPC-associated transcription factors, depletion of GATA2 markedly reduced expression of 
genes involved in the cell cycle and attenuated proliferation of CWR22Rv1 cells. 
 
Interestingly, after 48-hour knockdown of GATA2 in CWR22Rv1 cells, AR-V protein levels appeared 
to be diminished to a greater extent than AR-FL (Figure 1B and Supplementary Figure S9A), which is 
in contrast to prolonged GATA2 depletion which leads to a reduction in both AR-FL and AR-Vs [15, 
26]. GSEA of our GATA2 transcriptome identifies several spliceosome-related transcripts down-
regulated in response to GATA2 knockdown, including the characterised AR-FL/AR-V splicing factor 
SF3B3 [40] (Supplementary Figure S9B-E), supporting the concept that GATA2 may control synthesis 
of AR-Vs by enabling appropriate spliceosome composition. How this would impact on AR-Vs 
preferentially over the AR-FL in the short-term, however, is currently unclear, but given splicing is 
tightly linked to transcriptional elongation rates [41-43], GATA2 depletion may enable synthesis of 
AR-FL at the expense of AR-Vs. Further investigation is required to determine the mechanism by 
which this sequential downregulation occurs. It is likely that GATA2 regulates AR expression by 
multiple mechanisms which are not mutually exclusive. Taken together, we have conclusively shown 
that GATA2 is a pioneer factor for AR-V-mediated transactivation and functions to control other 
transcriptional regulators to enable maintenance of the CRPC phenotype. 
 
The notion that GATA2 represents an important therapeutic target in CRPC is supported by our data, 
but selective inhibitors of GATA2 are currently not available for both pre-clinical and clinical studies. 
Although GATA2 blockade in vitro and in vivo has been achieved with the small molecule inhibitor 
K7174 [26], how efficacious this compound is in the clinical setting remains unknown. Therefore, it is 
important to identify other modes of GATA2 regulation that can be exploited therapeutically with 
clinically-relevant drugs. Recently, inhibitors of the BET family of proteins, including BRD2, BRD3 and 
BRD4, have shown utility in down-regulating both AR-FL and AR-V chromatin occupancy and target 
gene expression in models of CRPC [13, 14]. The effect of BET inhibitors on AR-Vs is seemingly 
multifaceted with evidence indicating impact on both expression and transcriptional potency of AR-
Vs [13]. Critically however, interplay between BET proteins and pioneer factors has not been 
investigated in the context of CRPC. Considering that both BRD3 and BRD4 interact with acetylated 
GATA1 in the GIE erythroid cell line [36], we speculated that GATA2 and members of the BET family 
would interact in CRPC cell lines.  We demonstrated that GATA2 was acetylated and interacted with 
BRD2, BRD3 and a physiologically-relevant short derivative of BRD4, termed BRD4S. Importantly, we 
found that GATA2 interaction was mediated by BD1 of BRD4S and was sensitive to JQ1 treatment 
indicating a dependency on bromodomain function for the GATA2-BRD4S interaction. Given the high 
sequence homology between BRD4S and the longer BRD4L isoform, it is likely that the same degree 
of interplay exists between GATA2 and BRD4L.  
Close association between GATA2 and BRD4 at cis-regulatory enhancer elements of the PSA and 
TMPRSS2 genes, as demonstrated by GATA2/BRD4 re-ChIP experiments, suggested that interplay 
between GATA2 and BET proteins may be required for their chromatin occupancy in CRPC. ChIP-seq 
of GATA2 indicated that a large proportion of GATA2 genomic binding sites in VCaP cells were co-
occupied by BRD2, BRD3 and BRD4. Furthermore, JQ1 diminished GATA2 chromatin occupancy at a 
subset of GATA2-regulated genes indicating that there is a dependency on BET proteins for GATA2 
DNA binding at a cohort of genomic loci. How JQ1 is causing GATA2 chromatin disassociation is 
presently unclear, but widespread changes to the local chromatin environment, as a consequence of 
altered histone acetylation levels, may drive indiscriminate displacement of all transcriptional 
regulators from target loci [44]. However, analysis of FOXA1 deposition at AR-V-target gene cis-
regulatory elements suggests this is not the case, with chromatin occupancy of FOXA1 refractory to 
BET inhibition at the analysed loci. Instead, we speculate that blockade of the BD1-dependent 
interaction between GATA2 and BET proteins by JQ1 untethers GATA2 from co-occupied sites and is 
sufficient to diminish GATA2-chromatin binding. Importantly, experiments in VCaP and CWR22Rv1 
cells depleted of GATA2 demonstrated the existence of a reciprocal relationship between the two 
proteins whereby GATA2 is required for BRD4 chromatin association. This interdependency between 
the two proteins for cis-regulatory element binding may, again, be driven by a bromodomain-
dependent interaction between BRD2/BRD3/BRD4 and GATA2 or a consequence of diminished 
access of BET proteins to cis-regulatory elements through loss of pioneer factor activity. 
Interestingly, we identified a subset of GATA2 genomic binding sites which are co-occupied by BET 
proteins and are not impacted by JQ1. Visualisation of differentially bound GATA2 genomic binding 
sites in response to JQ1 indicated that GATA2 binding is more refractory to JQ1 treatment at sites 
which are most strongly bound by GATA2. It is possible that GATA2 presence at these strongly bound 
sites is mediated by other factors and BET proteins are less critical for GATA2 binding. However, it is 
also possible that there are subsets of BET genomic binding sites which are not impacted by JQ1 
which results in persistent GATA2 genomic binding. Additionally, we identified 363 GATA2 genomic 
binding sites which are altered in response to JQ1 treatment, but are not co-occupied by a BET 
protein. This may be explained by inhibition of other bromodomain containing proteins, such as 
p300 and ATAD2, with JQ1 which may also mediate GATA2 genomic binding, but have not been 
identified by this study. Future studies using Assay for Transposase-Accessible Chromatin (ATAC)-
sequencing and rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) will 
help to further assess interplay between GATA2 and BET proteins on chromatin and identify other 
GATA2 interacting bromodomain containing proteins. 
 
To gain an insight into the functional significance of interplay between GATA2 and BET proteins, we 
firstly examined potential clinical association of the genes neighbouring GATA2-binding peaks that 
were sensitive to JQ1 treatment. 916 genes were identified as being adjacent to GATA2 peaks from 
our cistromics data. Importantly, from this gene set, 245 were classified as upregulated in CRPC 
suggesting that GATA2 and BET family members control an important CRPC-associated gene 
signature that can be attenuated with BET inhibitors. We next assessed the functional dependency 
of GATA2-mediated transactivation on BET proteins by examining two LNCaP transcriptomes; one 
derived from depletion of GATA2 and one treated with the BET inhibitor I-BET762. GSEA of the two 
gene sets demonstrated that transcripts downregulated by treatment with I-BET762 were 
significantly negatively enriched for genes regulated by GATA2, suggesting that BET proteins control 
a considerable cohort of GATA2-regulated genes. Given that our cistromics data demonstrated 
reduced GATA2 chromatin occupancy at only 15% of global GATA2 binding sites in response to JQ1, 
dissociation of the pioneer factor from chromatin is likely to be one of several mechanisms of 
diminished GATA2 transcriptional competency in response to BET inhibitors. Loss of histone 
acetylation, leading to elevated chromatin compaction, or compromised binding/activity of other 
transcriptional co-regulators in response to BET inhibition will likely contribute to attenuated GATA2 
function without physical dissociation from DNA. Given that AR-FL and AR-V activity is sensitive to 
BET protein inhibition, it is possible that the effects of JQ1/I-BET762 on global GATA2 activity in 
CWR22Rv1 and VCaP cells could also be attributed to loss of AR from co-occupied GATA2 and AR 
bound genes. It is currently difficult to examine GATA2 transcriptional activity independently of AR 
because of the lack of AR-negative, GATA2-positive cell lines. To gain a more clear, precise read out 
of how BET inhibition effects GATA2 transcriptional activity these experiments will have to be 
conducted in an AR-negative system. 
Our data demonstrates that GATA2 is a critical regulator of AR-Vs and targeting GATA2 directly may 
offer new therapeutic strategies in the long-term. Furthermore, we have uncovered a critical 
interdependency between GATA2 and BET family members and demonstrate therapeutic 
sensitivities of GATA2 signalling to BET inhibitors that could be exploited in the short-term. In all, we 
have demonstrated that GATA2 drives global AR-V activity and have uncovered a CRPC-associated 
GATA2-driven gene expression signature that is sensitive to JQ1, suggesting that GATA2 and AR-V 
overexpressing CRPC will be sensitive to clinically-relevant BET inhibitors.  
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 Figure legends 
Figure 1: AR-V chromatin occupancy and transcriptional activity is dependent upon GATA2. A. 
CWR22Rv1 cells cultured in steroid-depleted conditions were transiently transfected with either 
control (siScr) or GATA2 (siGATA2) siRNAs for 24 hours prior to treatment ± 10 µM enzalutamide 
(Enz) for an additional 24 hours before RT-qPCR analysis of AR target genes. Graphs represent mean 
normalised gene expression (n=3) ± SEM (* = p ≤ 0.05, ns = p ≥ 0.05). B. CWR22Rv1 cells were 
cultured as above and effect of GATA2 knockdown on AR protein levels was assessed by western 
analysis. C. CWR22Rv1 cells were cultured in steroid-depleted conditions for 72 hours and subject to 
chromatin immunoprecipitation using an anti-GATA2 antibody or isotype control (IgG) antibody. 
Graphs represent mean normalised percentage input (n=3) ± SEM (* = p ≤ 0.05, ns = p ≥ 0.05). D. 
CWR22Rv1 cells cultured in steroid-depleted conditions were transiently transfected with either 
control (siScr) or GATA2 (siGATA2) siRNAs for 24 hours prior to treatment ± 10 µM enzalutamide 
(Enz) for an additional 24 hours prior to chromatin immunoprecipitation using an anti-AR (AR N-20) 
or isotype control (IgG) antibody. Graphs represent mean normalised percentage input (n=3) ± SEM 
(* = p ≤ 0.05, ns = p ≥ 0.05).   
 
Figure 2: GATA2 regulates oncogenic transcriptional activity in CRPC. A. CWR22Rv1 cells cultured in 
steroid-depleted media + 10 µM enzalutamide were depleted of AR-Vs, FOXA1 or GATA2 for 48 
hours. Differential gene expression was quantified by gene expression microarray analysis. Venn 
diagram shows the overlap of significantly deregulated genes in response to depletion of each 
protein. B. Gene signatures for GATA2 and AR-Vs were compared using Gene Set Enrichment 
Analysis (GSEA). Enrichment plots showing genes which are downregulated in response to AR-V 
depletion are negatively enriched for genes which are regulated GATA2 (left panel) and genes which 
are upregulated in response to AR-V depletion are positively enriched for genes which are regulated 
GATA2 (right panel). NES = normalised enrichment score, q = false discovery rate q-value. C. Genes 
which are induced by GATA2 (LogFC < 0.4) are overexpressed in two CRPC datasets as identified by 
Urbanucci et al., 2017. D. Genes which are induced by GATA2 (LogFC < 0.4) and overexpressed in 
CRPC (LogFC > 0.4) are AR-V regulated (LogFC < 0.4). E. The GATA2 gene signature was compared to 
‘GO’ datasets using Gene Set Enrichment Analysis (GSEA) and the top 5 most negatively enriched GO 
gene sets are shown. F. Enrichment plot shows the effect of GATA2 depletion on the 
GO_CELL_CYCLE gene set. NES = normalised enrichment score, q = false discovery rate q-value. G. 
CWR22Rv1 cells were cultured in steroid-depleted conditions and transfected with control (siScr) or 
GATA2 (siGATA2) siRNAs. Confluence was measured every 6 hours for 120 hours. Graph represents 
mean normalised confluence (n=3) ± SEM, (* = p ≤ 0.05, ns = p ≥ 0.05).  
 
Figure 3. GATA2 regulates the transcriptional activity of other oncogenic transcription factors. A. 
The GATA2 gene signature was compared to ‘Oncogenic signatures’ datasets using Gene Set 
Enrichment Analysis (GSEA). Graph shows the top 10 most negatively enriched oncogenic signatures. 
B. Enrichment plots show that the MYC_UP.V1_UP (left panel) and E2F1_UP.V1_UP (right panel) 
gene sets are negatively enriched for genes which are regulated by GATA2 in CWR22Rv1 cells. C. 
Enrichment plot shows genes which are induced by c-Myc overexpression in LNCaP cells are 
significantly negatively enriched for genes which are regulated by GATA2 in LNCaP cells. D. c-Myc 
and E2F1 genomic binding sites in LNCaP cells overlapped with GATA2 genomic binding sites in 
LNCaP cells.  
 
Figure 4: GATA2 is acetylated and interacts with BET proteins in a BD-dependent manner. A. 
HEK293T cells were transfected with empty vector (EV) or Flag-GATA2 for 48 hours and treated with 
a DMSO control or 5 µM trichostatin A (TSA) for 6 hours before immunoprecipitation (IP) with an 
anti-Flag antibody. Immunoprecipitates were subject to western blot analysis with anti-Flag or anti-
pan acetylated-lysine antibodies. B. HEK293T cells were transfected with an empty vector (EV) or 
Flag-BRD4-short (BRD4S) for 48 hours and treated with a DMSO control or 1 µM JQ1 for 24 hours 
before IP with an anti-GATA2 antibody. Immunoprecipitates were analysed by western blot using an 
anti-Flag antibody. C. HEK293T cells were transfected with an empty vector (EV), Flag-BRD4S BD1 
mutant (BRD4S mBD1), Flag-BRD4S BD2 mutant (BRD4S mBD2) for 48 hours before IP using an anti-
GATA2 antibody. Immunoprecipitates were subject to western blot using an anti-Flag antibody. D. 
HEK293T cells were transfected with an empty vector (EV), V5-BRD2 or V5-BRD3 for 48 hours before 
IP with an anti-GATA2 antibody. Immunoprecipitates were analysed by western blot using an anti-V5 
antibody. For each IP, input samples were probed for Flag and α-tubulin. E. VCaP cells cultured in 
steroid-depleted conditions for 72 hours were subject to chromatin immunoprecipitation (ChIP) 
using an anti-BRD4 antibody and then re-ChIP using either anti-GATA2 or isotype control (IgG) 
antibodies prior to quantitative PCR analysis. F. VCaP cells cultured in steroid-depleted conditions 
were transiently transfected with control (siScr) or GATA2 (siGATA2) siRNAs for 48 hours prior to 
ChIP using anti-BRD4 or isotype control (IgG) antibodies and quantitative PCR analysis. G. VCaP cells 
were cultured as in (E) and treated for 24 hours with either vehicle or 1 µM JQ1 prior to chromatin 
immunoprecipitation using either an anti-GATA2 or isotype control (IgG) antibody. Graphs represent 
mean normalised percentage input (n=3) ± SEM (* = p ≤ 0.05, ns = p ≥ 0.05). 
 
Figure 5: JQ1 reduces GATA2 chromatin deposition genome-wide. A. Motif analysis on the 100 
most strongly bound GATA2 ChIP-seq peaks. B. GATA2 ChIP-seq peaks annotated to gene features. 
C. Visualisation of the read intensity across the 1,022 sites (-/+ 2 kb) at which GATA2 binding affinity 
is decreased upon JQ1 treatment. D. GATA2 genomic binding sites identified in VCaP cells 
overlapped with BRD2, BRD3 and BRD4 genomic binding sites [14]. E. Visualisation of AR -/+ DHT, 
GATA2, GATA2 + JQ1, BRD2, BRD3 and BRD4 peaks upstream of PSA (KLK3), KLK2 and TMPRSS2.  
 
Figure 6: BET protein inhibition regulates GATA2 regulated gene expression. A. Gene signatures for 
GATA2 and 0.5 µM I-BET762 were compared using Gene Set Enrichment Analysis (GSEA) with 
enrichment plots showing genes which are downregulated in response to 0.5 µM I-BET762 
treatment are negatively enriched for genes which are regulated GATA2 (left panel) and genes which 
are upregulated in response to 0.5 µM I-BET762 treatment are positively enriched for genes which 
are regulated GATA2 (right panel). NES = normalised enrichment score, q = false discovery rate q-
value. B. PRIM1, TRIM14 and RAP1GAP expression were assessed in 29 benign prostatic hyperplasia 
(BPH) samples, 131 localised prostate cancer (PCa) samples and 19 metastatic castrate-resistant 
prostate cancer (mCRPC) samples [28]. Outliers are shown as ●, ▪ and ▲ respectively, (* = p ≤ 0.05, 
ns = p ≥ 0.05). C. Visualisation of GATA2, GATA2 + JQ1, BRD2, BRD3 and BRD4 enrichment upstream 
of PRIM1, TRIM14 and RAP1GAP. D. VCaP cells cultured in steroid-depleted conditions were treated 
for 24 hours with control (NT) or 1 µM JQ1 prior to chromatin immunoprecipitation using an anti-
GATA2 or isotype control (IgG) antibody. Graph represents normalised % input of at least n=2 ± SEM 
(* = p ≤ 0.05, ns = p ≥ 0.05). E. VCaP cells cultured in steroid-depleted conditions were transiently 
transfected with control (siScr) or GATA2 (siGATA2) siRNAs for 72 hours prior to RT-qPCR assessing 
PRIM1 mRNA expression. Graphs represent mean normalised gene expression, n=3 ± SEM (* = p ≤ 
0.05, ns = p ≥ 0.05). F. VCaP cells were cultured as in (D) before RT-qPCR assessing PRIM1 mRNA 
expression. Graphs represent mean normalised gene expression, n=3 ± SEM (* = p ≤ 0.05, ns = p ≥ 
0.05). G. PRIM1, TRIM14 and RAP1GAP mRNA expression in response to a 24-hour 0.5 and 10 µM I-
BET762 treatment [31]. Graph represents gene expression, n=2 ± SEM (* = p ≤ 0.05, ns = p ≥ 0.05). 
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Supplementary figure legends 
 
Supplementary Figure S1. A. CWR22Rv1 cells cultured in steroid‐depleted conditions were transiently 
transfected with control (siScr) or GATA2 (siGATA2) siRNAs for 24 hours prior to treatment with ± 10 
µM enzalutamide (Enz) for an additional 24 hours before RT‐qPCR analysis of PSA, KLK2 and UBE2C 
mRNA expression. Graphs represent mean normalised gene expression (n=3) ± SEM (* = p ≤ 0.05, ns 
= p ≥ 0.05). B. Visualisation of GATA2 and AR (‐/+ DHT) peaks at PSA (KLK3), KLK2, TMPRSS2 and UBE2C 
genes. 
 
Supplementary  Figure  S2. Chromatin  fractions  from CWR22Rv1  cells  cultured  in  steroid‐depleted 
conditions for 24 hours and then treated with 10 µM enzalutamide for an additional 24 hours were 
subject to western analysis using anti‐GATA2, anti‐AR (N20) and anti‐histone H1 antibodies.  
 
Supplementary Figure S3. Venn diagrams showing differentially‐expressed genes in CWR22Rv1 cells 
depleted of GATA2 and AR‐Vs for 48 hours; A. representing down‐regulated genes by 1.5‐fold or more 
(LogFC ≤ ‐0.586, p ≤ 0.05); B. representing up‐regulated genes by 1.5‐fold or more (LogFC ≥ 0.586, p ≤ 
0.05). CDC25A and EXO1 mRNA was quantified by RT‐qPCR. Graphs represent mean normalised gene 
expression (n=3) ± SEM (* = p ≤ 0.05, ns = p ≥ 0.05).  
 
Supplementary  Figure  S4.  A.  Venn  diagrams  showing  overlaps  between  GATA2‐regulated  genes 
(LogFC ≤ ‐0.4) and genes overexpressed in CRPC (LogFC ≥ 0.4). Gene ontology analysis indicated that 
these genes are involved in a range of processes (top 6 most significantly deregulated Gene ontology 
(GO)  biological  processes  terms  shown).  B.  CWR22Rv1  cells  were  cultured  in  steroid‐depleted 
conditions and  transiently  transfected with control  (siScr) or GATA2  (siGATA2)  siRNAs. Cell counts 
were performed after 96 hours. Graph represents mean normalised cell count (n=3) ± SEM, (* = p ≤ 
0.05, ns = p ≥ 0.05). 
 
Supplementary  Figure  S5.  A.  VCaP  cells  cultured  in  steroid‐depleted  conditions were  transiently 
transfected with control (siScr) or GATA2 (siGATA2) siRNAs for 48 hours prior to western analysis of  
GATA2, BRD4 and p300. B. VCaP cells cultured  in  steroid‐depleted conditions were  treated  for 24 
hours with vehicle control or 1 µM JQ1 prior to western analysis of GATA2. C. CWR22Rv1 cells cultured 
in steroid‐depleted conditions were treated for 24 hours with vehicle control (NT) or 1 µM JQ1 prior 
to chromatin  immunoprecipitation using anti‐GATA2,  ‐anti AR  (AR(BD)),  ‐anti BRD4 and an  isotype 
control (IgG) antibodies. Graphs represent normalised % input, graphs represent at least n=2 ± SEM 
(*  =  p  ≤  0.05,  ns  =  p  ≥  0.05).  D.  VCaP  cells were  cultured  as  above  and  subject  to  chromatin 
immunoprecipitation  using  an  anti‐FOXA1  or  isotype  control  (IgG)  antibodies.  Graphs  represent 
normalised % input, n=3 ± SEM, (* = p ≤ 0.05, ns = p ≥ 0.05). 
 
Supplementary Figure S6. A. Venn diagram representing the number of overlapping peaks in the ‘Non‐
treated GATA2 ChIP‐seq N1’ and ‘Non‐treated GATA2 ChIP‐seq N2’ peak sets (q < 0.05). B. Visualisation 
3 
 
of peaks for the GATA2 ‐/+ 1 µM JQ1 ChIP‐seq samples upstream of PSA (KLK3), KLK2 and TMPRSS2. 
C. Volcano plot showing the  impact of 1 µM JQ1 on GATA2 genomic binding affinity. Log2(GATA2)‐
log2(JQ1) denotes the change in binding affinity at each site in response to JQ1. ‐log10(FDR) indicates 
the significance of binding affinity change. Pink dots represent significantly (FDR ≤ 0.05) differentially 
bound GATA2 binding sites. D. MA plot showing the impact of 1 µM JQ1 on GATA2 genomic binding 
affinity. Log GATA2 binding affinity denotes the binding affinity of GATA2 at each genomic site. Log 
fold change (GATA2‐JQ1GATA2) represents the magnitude of the change in GATA2 binding affinity in 
response  to  1 µM  JQ1.  Pink  dots  represent  significantly  (FDR  ≤  0.05)  differentially bound GATA2 
binding sites. 
 
Supplementary Figure S7. A. Non‐treated GATA2 N2 peak set  in VCaP cells overlapped with BRD2, 
BRD3 and BRD4 peaks. B. Differentially bound GATA2 sites were overlapped with BRD2, BRD3, and 
BRD4; sites at which GATA2 affinity increases (upper panel) and decreases (lower panel) in response 
to 1 µM JQ1 (18) overlapped with BET proteins.  
 
Supplementary Figure S8.  A. Genes proximal to differentially bound GATA2 sites in response 1 µM 
JQ1 were overlapped with genes which are overexpressed (LogFC > 0.4) in CRPC (left panel). Genes 
which possessed a differentially bound GATA2 site within the transcriptional start sites (TSS) (‐/+ 10 
kb from TSS)  in response 1 µM JQ1 were overlapped with genes which are overexpressed (LogFC > 
0.4)  in  CRPC  (right  panel).  B.  Significantly  deregulated  (LogFC  ≠  0)  genes  in  response  to  GATA2 
depletion in LNCaP cells were overlapped with genes which are highly deregulated (2 < LogFC < ‐2) by 
0.5 µM I‐BET762 for 24 hours in LNCaP cells (left panel). Significantly down‐regulated (LogFC < 0) genes 
in response to GATA2 depletion in LNCaP cells were overlapped with genes which are highly down‐
regulated (LogFC < 2) by 0.5 µM I‐BET762 for 24 hours in LNCaP cells (middle panel). Significantly up‐
regulated (LogFC > 0) genes in response to GATA2 depletion in LNCaP cells were overlapped with genes 
which are highly down‐regulated (LogFC > 2) by 0.5 µM  I‐BET762 for 24 hours  in LNCaP cells (right 
panel). C. CWR22Rv1 cells cultured in steroid‐depleted conditions were transiently transfected with 
control (siScr) or GATA2 (siGATA2) siRNAs for 24 hours prior to treatment with 10 µM enzalutamide 
(Enz)  for an additional 24 hours before quantitative PRIM1 mRNA expression by RT‐qPCR. Graphs 
represent normalised gene expression, n=3 ± SEM (* = p ≤ 0.05, ns = p ≥ 0.05).  
 
Supplementary  Figure  S9.  A.  CWR22Rv1  cells  cultured  in  steroid‐depleted  were  transiently 
transfected  with  control  (siScr)  or  GATA2  (siGATA2)  siRNAs  in  the  presence  and  absence  of 
enzalutamide  for 48 hours before AR‐V7 and AR‐FL mRNA expression analysis by RT‐qPCR. Graphs 
represent normalised gene expression n=3 ± SEM (* = p ≤ 0.05, ns = p ≥ 0.05). B. Enrichment plots 
showing genes in the KEGG_SPLICOSOME are negatively enriched for genes which are regulated by 
GATA2  (NES = normalised enrichment score, q =  false discovery q‐value). C. CWR22Rv1 cells were 
cultured  in  steroid‐depleted  media  in  the  presence  of  10  µM  enzalutamide  were  transiently 
transfected with control  (siScr) or GATA2  (siGATA2) siRNAs  for 48 hours before analysis of SF3B3, 
DDX46 and SNRBP mRNA by RT‐qPCR. Graphs represent normalised gene expression n=3 ± SEM (* = 
p ≤ 0.05, ns = p ≥ 0.05). D. CWR22Rv1 cells were cultured as above were transiently transfected with 
two SF3B3 siRNAs (siSF3B3 oligo 1 and siSF3B3 oligo 2) or control (siScr) for 48 hours before mRNA 
levels of SF3B3, AR‐V7 and AR‐FL mRNA were measured by RT‐qPCR. Graphs represent normalised 
gene expression n=3 ± SEM (* = p ≤ 0.05, ns = p ≥ 0.05). E. CWR22Rv1 cells cultured in steroid‐depleted 
4 
 
conditions were transiently transfected with siScr or siSF3B3 oligo 1 and confluence measured every 
6 hours for 120 hours. Graph represents mean normalised confluence (n=3) ± SEM, (* = p ≤ 0.05, ns = 
p ≥ 0.05). 
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